Hematological malignancies are associated with a lower interferon-a blocking activity than solid tumors

Area of Science:

• Oncology
• Immunology
• Biochemistry

Background:

• Interferon-alpha (IFN-alpha) demonstrates anti-tumor effects in various cancers.
• IFN inhibitors are linked to treatment ineffectiveness in malignant neoplasias.
• Understanding IFN inhibitor incidence may clarify differential patient responses to IFN therapy.

Purpose of the Study:

• To investigate the prevalence of serum IFN-inhibiting activity in patients with hematological malignancies versus solid tumors.
• To explore the role of IFN inhibitors in explaining varied responses to IFN treatment.

Main Methods:

• Serum samples were collected from 90 patients with solid tumors and 46 with hematological malignancies, plus 50 healthy controls.
• Interferon-inhibiting activity and endogenous IFN-like activity were assessed using an IFN-sensitive cell line.

Main Results:

• No endogenous IFN-like activity was detected in any group.
• IFN-blocking activity was significantly lower in hematological malignancy patients (21.7%) compared to solid tumor patients (56.6%, P<0.001).
• Both patient groups showed higher IFN-blocking activity than controls (P<0.01).

Conclusions:

• A lower percentage of IFN inhibitors in sera from hematological malignancy patients was observed.
• This finding may partially explain the superior response of hematological malignancies to IFN treatment.